-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the improvement of living standards, the prevalence of metabolic liver disease, including non-alcoholic fatty liver disease and alcohol-related liver disease, is increasing, which eventually leads to an increase in end-stage liver disease (liver failure, cirrhosis, liver cancer).
data show that hundreds of millions of people worldwide are affected by liver disease.
as many as 7 million people in China suffer from cirrhosis, with 460,000 new cases of liver cancer each year.
guidelines recommend strengthening early detection of liver disease and its treatment in primary care to identify early cirrhosis.
a recent study published in the journal BMJ Open, researchers developed a CIRRUS algorithm that predicts advanced liver disease with an accuracy of about 90 percent.
In the study, researchers performed a Logistic regression analysis of blood data routinely collected by the University Hospital of Southampton (UHS) information system and based it on the AdvLD model, and then validated predictions of first severe liver events (SLE) in two queues of 394,253 (UHS: primary and secondary care) and 183,045 (CHIE: primary care care and health information).
, UHS and CHIE validation queues recorded 3,044 cases (0.8%) and 1,170 (0.6%) SLE, respectively.
in the UHS queue, CIRRUS predicts SLE for the first time in five years, with a continuous curve area of 0.90 (0.89 to 0.91) and a 0.88 (0.87 to 0) area under the continuous curve. .89) (dark red, red, amber, green grade); CHIE queue AAUC is 0.84 (0.82 to 0.86) and 0.83 (0.81 to 0.85).
In patients with specific liver risk factors (alcohol, diabetes, viral hepatitis), the crimson/red threshold predicts first SLE, UHS and CHIE queue sensitivity of 72% and 59%, specificity of 87% and 93%, positive predictions of 26% and 18%, and negative predictions of 98% and 99%.
"This new CIRRUS algorithm can be used in routine blood tests," said the researchers, who analyzed the area under the curve of the validation dataset 1 (UHS) and validation dataset 2 (CHIE) to predict the index's severe liver event (SLE) test over a five-year date.
most cases, the liver can recover even if late-stage patients can address the cause by changing their lifestyle, stopping drinking or losing weight.
all of us are plagued by a coronavirus pandemic, we cannot ignore the causes of other potentially preventable deaths and serious diseases.
detect serious liver disease early through routine blood test data, which may reduce emergency hospitalization and serious health conditions.
" In short, cirrhosis is a silent killer, and the CIRRUS algorithm is designed to identify the risk of advanced liver disease based on routine blood tests (albumin, creatinine, bilirin, average red blood cell volume, sodium, platelet count, protein).
unlike most diagnostic liver algorithms, the CIRRUS model was created using data sets from primary and secondary health care patients and is more suitable for screening for liver disease outside of secondary health care hepatology.